PE Picks, Podcast Episode 13, and Executive Profiles

In this ISSUE

Enabling Cultural Change in Organizations

FDA Opens Door to Importing Scarce and Costly Drugs

Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersys

Reconstructing

Does the Pfizer Restructuring Make Sense?

The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
... /Read more/

A Framework for Successful Biopharma Launches Understanding the launch archetype and identifying critical success factors
On Demand

Learn more

Opinion

The Key to Better Navigating VUCA Industry Conditions

Alison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.
... /Read more/

Calendar

/ 12th Annual Forum on Transparency and Aggregate Spend 8/13-8/15 /

/ 4th Bio/Pharmaceutical Product Launch Summit 9/25-9/26 /

/ American Pharma Outsourcing Summit 10/2-10/3 /

/ 28th Annual Sharing Conference: Compliance 10/15-10/17 /

/ Basket & Umbrella Trials for Oncology 10/17-10/18 /

/ Crossroads: An Artia Solutions Conference 11/7-11/9 /

Oyster Point Pharma

The Pharm Exec Podcast: Episode 13

Jeffrey Nau is CEO of Oyster Point Pharma, a clinical stage pharmaceutical company focused on developing commercial therapies dealing with parasympathetic pathways. In a climate where oncology and rare diseases get most of the attention, Nau talks about what it's like working on diseases that don't get the same press, like dry eye, which is the focus of their current Phase 2 clinical trial. How this impacts raising capital and other bumps in the road he has come across. Having extensive experience with raising startup money, Nau outlines some best practices when it comes to funding.
... /Read more/

R&D

Optimizing the Digital Opportunity in Biopharmaceutical R&D

If advanced technologies hold the key to at least some of the productivity issues R&D organizations need to overcome, Nicholas Lakin asks what are the best strategies and operating models for exploiting these aids to their fullest potential.
... /Read more/

The FDA

Gottlieb Reshapes FDA to Elevate Centers, Streamline Policymaking

Scott Gottlieb is proposing to flatten out FDA's structure by having Center directors report directly to him, giving more authority to the agency's six product regulatory Centers and to the Office of Regulatory Affairs.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com